The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | MEDI-570: a novel antibody therapy in R/R T-cell lymphoma
Julio Chavez, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the results of a Phase I, dose-escalation study (NCT02520791) aiming to evaluate the safety and efficacy of an anti-ICOS monoclonal antibody, MEDI-570, in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL). In a group of 17 patients with either PTCL or AITL, no dose-limiting toxicities (DLTs) were reported and the maximum tolerated dose (MTD) was not reached. A partial response (PR) was seen in four AITL patients, regardless of the dosage used. Durable responses could also be seen in the participants who achieved PR. While 65% of the patients experienced side effects in the form of a low CD4+ T-cell count, the overall safety profile of MEDI-570 was found tolerable. Flow cytometry analysis showed that following MEDI-570 treatment, the populations of ICOS-positive T-cells were decreased but other cell types, including B-cells were not affected. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
